Class II recall: Pfizer: Dopamine HCl Inj., USP, 200 mg/5 mL (40 mg/mL), 5 mL Single-dose, 25 vials per t

The recall notice reports a Class II recall of Dopamine HCl Inj., USP, 200 mg/5 mL (40 mg/mL), 5 mL single-dose vials, distributed by Hospira, Inc. The notice states the reason for recall as lack of assurance of sterility, affecting vials with NDC 0409-5820-11 and cartons with NDC 0409-5820-01.

Most relevant for: Clinicians and facilities that administer injectable dopamine, such as in hospital or acute care settings using this product for hemodynamic support.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.